Wang, YZ (reprint author), Shanghai Inst Biol Sci, State Key Lab Neurosci, Inst Neurosci, 320 Yueyang Rd, Shanghai 200031, Peoples R China,firstname.lastname@example.org
Metastatic hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide. However, the cell population responsible for its metastasis remains largely unknown. Here, we reported that CD133(+) CD44(+/high) defined a subgroup of tumor cells that was responsible for hematogenous metastasis of liver cancers. Immunohistochemical investigation of human HCC specimens revealed that the number of CD133(+) and CD44(+) HCC cells was increased and was associated with portal vein invasion. Purified CD133(+) or CD44(high) HCC cells were superior in clonogenic growth and vascular invasion, respectively. Thus, the combination of CD133 and CD44 was used to define a novel HCC sub-population. CD133(+) CD44(high), but not CD133(+) CD44(low/-), CD133-CD44(high) or CD133-CD44(low/-) xenografts, produced intrahepatic or lung metastasis in nude mice. Further analysis of human HCC samples by flow cytometry showed that the number of CD133(+) CD44(+) tumor cells was associated with portal vein metastasis. The cDNA microarray analysis of CD133(+) CD44(+) and CD133(+) CD44-tumor cells isolated from metastatic HCC patients revealed that these cells comprised of two different populations possessing distinct gene expression profiles. Our results suggest that CD133(+) CD44(+) tumor cells are a particular population responsible for hematogenous metastasis in liver cancers and that these cells might be targets for treatment of HCC metastasis.